Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice

Radiat Res. 2008 Apr;169(4):474-8. doi: 10.1667/RR1245.1.

Abstract

It was hypothesized that histone deacetylase (HDAC) inhibitors may increase survival after total-body irradiation (TBI) based on previous reports demonstrating that HDAC inhibitors stimulate the proliferation of bone marrow stem cells. Using the time for mice to lose 20% or more of their weight as the end point, two HDAC inhibitors, valproic acid and trichostatin-A, were found to reduce lethality in a dose-dependent manner. HDAC inhibitors were effective at reducing lethality when given either 24 h before or 1 h after TBI. The results indicate that HDAC inhibitors have potential for protecting against and mitigating radiation-induced lethality.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology*
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / radiation effects
  • Histone Deacetylase Inhibitors*
  • Hydroxamic Acids / pharmacology
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Radiation-Protective Agents / pharmacology*
  • Valproic Acid / pharmacology
  • Whole-Body Irradiation*

Substances

  • Enzyme Inhibitors
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Radiation-Protective Agents
  • trichostatin A
  • Valproic Acid